FluView by National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division.
  
2015-2016 Influenza Season 
Week 44 ending November 7, 2015 
All data are preliminary and may change as more reports are received. 
 
Synopsis: During week 44 (November 1-7, 2015), influenza activity was low in the United States. 
o Viral Surveillance: The most frequently identified influenza virus type reported by public 
health laboratories in week 44 was influenza A viruses, with influenza A (H3) viruses 
predominating.  The percentage of respiratory specimens testing positive for influenza in 
clinical laboratories is low. 
o Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and 
influenza (P&I) was below their system-specific epidemic threshold in both the NCHS 
Mortality Surveillance System and the 122 Cities Mortality Reporting System.  
o Influenza-associated Pediatric Deaths: No influenza-associated pediatric deaths were 
reported. 
o Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness 
(ILI) was 1.4%, which is below the national baseline of 2.1%. All 10 regions reported ILI 
below region-specific baseline levels. Puerto Rico experienced moderate ILI activity, New 
York City and 50 states experienced minimal ILI activity, and the District of Columbia had 
insufficient data. 
o Geographic Spread of Influenza: The geographic spread of influenza in Guam was 
reported as widespread; Puerto Rico reported regional activity; four states reported local 
activity; the District of Columbia and 39 states reported sporadic activity; and the U.S. Virgin 
Islands and seven states reported no influenza activity. 
 
National and Regional Summary of Select Surveillance Components 
 
HHS 
Surveillance 
Regions* 
Data for current week Data cumulative since October 4, 2015 (week 40) 
Out-
patient 
ILI† 
Number of  
jurisdictions 
experiencing 
high or 
moderate ILI 
activity§ 
% respiratory 
specimens 
positive for 
flu in clinical 
laboratories‡ 
A(H1N1)
pdm09 A (H3) 
A 
(Subtyping 
not 
performed) 
B 
Victoria 
lineage 
B 
Yamagata 
lineage 
B lineage 
not 
performed 
Pediatric 
Deaths 
Influenza test results from public health laboratories only 
Nation Normal 1 of 53 1.2% 25 165 8 5 2 35 0 
Region 1 Normal 0 of 6 0.4% 2 12 0 0 0 0 0 
Region 2 Normal 1 of 4 0.5% 7 10 0 0 0 2 0 
Region 3 Normal 0 of 6 1.1% 3 6 2 0 0 0 0 
Region 4 Normal 0 of 8 2.7% 1 15 0 0 0 6 0 
Region 5 Normal 0 of 6 0.7% 11 16 1 0 1 0 0 
Region 6 Normal 0 of 5 1.1% 0 10 0 1 0 5 0 
Region 7 Normal 0 of 4 0.9% 0 20 1 1 1 0 0 
Region 8 Normal 0 of 6 0.3% 0 5 1 2 0 0 0 
Region 9 Normal 0 of 4 1.1% 1 50 2 1 0 22 0 
Region 10 Normal 0 of 4 0.3% 0 21 1 0 0 0 0 
 
*http://www.hhs.gov/about/agencies/staff-divisions/iea/regional-offices/index.html 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
§ Includes all 50 states, New York City, the District of Columbia, and Puerto Rico 
‡ National data are for current week; regional data are for the most recent three weeks. 
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U.S. Virologic Surveillance: WHO and NREVSS collaborating laboratories, which include both 
public health and clinical laboratories located in all 50 states, Puerto Rico, and the District of 
Columbia, report to CDC the total number of respiratory specimens tested for influenza and the 
number positive for influenza virus type. In addition, public health laboratories also report the 
influenza A subtype (H1 or H3) and influenza B lineage information of the viruses they test and the 
age or age group of the persons from whom the specimens were collected.   
 
Additional data are available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
 
The results of tests performed by clinical laboratories are summarized below. 
 
 Week 44 Data Cumulative since October 4, 2015 (week 40) 
No. of specimens tested 10,271 58,544 
No. of positive specimens (%) 128 (1.2%) 705 (1.2%) 
Positive specimens by type   
Influenza A 75 (58.6%) 457 (64.8%) 
Influenza B 53 (41.4%) 248 (35.2%) 
 
Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, 
National Summary, 2015-16 Season 
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The results of tests performed by public health laboratories, as well as the age group distribution of 
influenza positive tests, are summarized below. 
 
 Week 44 Data Cumulative since October 4, 2015 (week 40) 
No. of specimens tested 606 4,503 
No. of positive specimens 18 240 
Positive specimens by type/subtype   
Influenza A 10 (55.6%) 198 (82.5%) 
          A(H1N1)pmd09 1 (10.0%) 25 (12.6%)
          H3 7 (70.0%) 165 (83.3%)
          Subtyping not performed 2 (20.0%) 8 (4.0%)
Influenza B 8 (44.4%) 42 (17.5%) 
          Yamagata lineage 0 (0%) 2 (4.8%)
          Victoria lineage 1 (12.5%) 5 (11.9%)
          Lineage not performed 7 (87.5%) 35 (83.3%)
 
Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, 
National Summary, 2015-16 Season 
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Age Group Distribution of Influenza Positive Specimens Reported by Public 
Health Laboratories, National Summary, 2015-16 Season 
Weekly Cumulative
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Age Group Proportions and Total by Influenza Subtype Reported by Public 
Health Laboratories, 2015-16 Season 
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Influenza Virus Characterization: CDC characterizes influenza viruses through one or more tests 
including genome sequencing, hemagglutination inhibition (HI), and/or neutralization assays. This 
data is used to compare how similar currently circulating influenza viruses are to the reference 
viruses used for developing influenza vaccines, and to monitor for changes in circulating influenza 
viruses. Historically, HI data has been used most commonly to assess the similarity between 
reference viruses and circulating viruses as a proxy for vaccine effectiveness. Beginning in the 
2014–2015 season and to date, however, a portion of influenza A (H3N2) viruses did not yield 
sufficient hemagglutination titers for antigenic characterization by HI. For many of these viruses, 
CDC performs genetic characterization to determine the genetic group identity of circulating viruses. 
In this way, antigenic properties of these viruses can be inferred from viruses within the same 
genetic group that have been characterized antigenically. 
 
CDC has characterized 335 influenza viruses [14 A (H1N1)pdm09, 250 A (H3N2), and 71 influenza B 
viruses] collected by U.S. laboratories during May 24-September 30, 2015. 
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Influenza A Virus [264]  
 
A (H1N1)pdm09 [14]: All 14 (100%) influenza A (H1N1)pdm09 viruses were antigenically 
characterized as A/California/7/2009-like, the influenza A (H1N1) component of the 2015-2016 
Northern Hemisphere. 
  
A (H3N2) [250] 
 All 250 H3N2 viruses were genetically sequenced and all viruses belonged to genetic 
groups for which a majority of viruses antigenically characterized were similar to 
A/Switzerland/9715293/2013, the influenza A (H3N2) component of the 2015-2016 Northern 
Hemisphere vaccine. 
 A subset of 104 H3N2 viruses also were antigenically characterized; 103 of 104 (99%) 
H3N2 viruses were A/Switzerland/9715293/2013-like by HI testing or neutralization testing. 
  
Influenza B Virus [71]: Forty-four (62%) of the influenza B viruses characterized belonged to 
B/Yamagata/16/88 lineage and the remaining 27 (38%) influenza B viruses characterized belonged 
to B/Victoria/02/87 lineage. 
  
Yamagata Lineage [44]: All 44 (100%) B/Yamagata-lineage viruses were antigenically 
characterized as B/Phuket/3073/2013-like, which is included as an influenza B component of the 
2015-2016 Northern Hemisphere trivalent and quadrivalent influenza vaccines. 
  
Victoria Lineage [27]: All 27 (100%) B/Victoria-lineage viruses were antigenically characterized as 
B/Brisbane/60/2008-like, the virus that is included as an influenza B component of the 2015-2016 
Northern Hemisphere quadrivalent influenza vaccine. 
 
CDC has characterized 10 influenza viruses [one A (H1N1)pdm09, eight A (H3N2), and one 
influenza B virus] collected by U.S. laboratories since October 1, 2015. 
 
The eight influenza A (H3N2) viruses collected since October 1, 2015 have been genetically 
sequenced and all viruses belonged to genetic groups for which a majority of viruses antigenically 
characterized were similar to A/Switzerland/9715293/2013, the influenza A (H3N2) component of 
the 2015-2016 Northern Hemisphere vaccine.  Six viruses (one A (H1N1)pdm09, four A (H3N2), 
and one B/Yamagata-lineage) collected since October 1, 2015 have been antigenically 
characterized. All six were similar to the 2015-2016 Northern Hemisphere influenza vaccine 
components. 
 
 
Antiviral Resistance: Testing of influenza A(H1N1)pdm09, A(H3N2), and influenza B virus isolates 
for resistance to neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) is performed at 
CDC using a functional assay. Additional A(H1N1)pdm09 and A(H3N2) clinical samples are tested 
for mutations of the virus known to confer oseltamivir resistance. The data summarized below 
combine the results of both testing methods. These samples are routinely obtained for surveillance 
purposes rather than for diagnostic testing of patients suspected to be infected with antiviral-
resistant virus. 
 
High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 
A(H1N1)pdm09 and A(H3N2) viruses (the adamantanes are not effective against influenza B 
viruses). Therefore, data from adamantane resistance testing are not presented below. 
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Neuraminidase Inhibitor Resistance Testing Results 
on Samples Collected Since October 1, 2015 
 
Oseltamivir Zanamivir Peramivir 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Influenza 
A(H1N1)pmd09 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 
Influenza A 
(H3N2) 13 0 (0.0) 13 0 (0.0) 13 0 (0.0) 
Influenza B 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 
 
The majority of recently circulating influenza viruses are susceptible to the neuraminidase inhibitor 
antiviral medications, oseltamivir, zanamivir, and peramivir; however, rare sporadic instances of 
oseltamivir-resistant and peramivir-resistant influenza A (H1N1)pdm09 and oseltamivir-resistant 
influenza A (H3N2) viruses have been detected worldwide. Antiviral treatment is recommended as 
early as possible for patients with confirmed or suspected influenza who have severe, complicated, 
or progressive illness; who require hospitalization; or who are at high risk for serious influenza-
related complications. Additional information on recommendations for treatment and 
chemoprophylaxis of influenza virus infection with antiviral agents is available at 
http://www.cdc.gov/flu/antivirals/index.htm. 
 
 
 
 
 
 
Pneumonia and Influenza (P&I) Mortality Surveillance: Rapid tracking of pneumonia and 
influenza-associated deaths is done through two systems, the National Center for Health Statistics 
(NCHS) Mortality Surveillance System and the 122 Cities Mortality Reporting System. NCHS 
mortality surveillance data are presented by the week the death occurred and P&I percentages are 
released two weeks after the week of death to allow for collection of enough data to produce a 
stable P&I percentage. Users of the data should not expect the two systems to produce the same 
percentages, and the percent P&I deaths from each system should be compared to the 
corresponding system-specific baselines and thresholds. 
 
NCHS Mortality Surveillance Data:  
Based on NCHS mortality surveillance data available on November 12, 2015, 5.8% of the deaths 
occurring during the week ending October 24, 2015 (week 42) were due to P&I. This percentage is 
below the epidemic threshold of 6.5% for week 42.  
 
Region and state-specific data are available at http://www.cdc.gov/flu/weekly/nchs.htm. 
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Pneumonia and Influenza Mortality from 
the National Center for Health Statistics Mortality Surveillance System 
Data through the week ending October 24, 2015, as of November 12, 2015 
4
6
8
10
12
40 50 10 20 30 40 50 10 20 30 40 50 10 20 30 40 50 10 20 30 40
%
 o
f A
ll 
D
ea
th
s 
D
ue
 to
 P
&
I  
MMWR Week
Epidemic Threshold
Seasonal Baseline
2011 2012 2013 2014 2015
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2015-16 Influenza Season – Week 44, ending November 7, 2015           
 
 
 
 
9
 
122 Cities Mortality Reporting System  
During week 44, 5.7% of all deaths reported through the 122 Cities Mortality Reporting System 
were due to P&I. This percentage was below the epidemic threshold of 6.2% for week 44. 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending November 7, 2015 
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Influenza-Associated Pediatric Mortality: No influenza-associated pediatric deaths were reported 
to CDC during week 44. 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2012-2013 season to present 
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Influenza-Associated Hospitalizations: The Influenza Hospitalization Surveillance Network 
(FluSurv-NET) conducts all age population-based surveillance for laboratory-confirmed influenza-
related hospitalizations in select counties in the Emerging Infections Program (EIP) states and 
Influenza Hospitalization Surveillance Project (IHSP) states. FluSurv-NET estimated hospitalization 
rates will be updated weekly starting later this season. Additional FluSurv-NET data can be found 
at: http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html and 
http://gis.cdc.gov/grasp/fluview/FluHospChars.html. 
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Outpatient Illness Surveillance: Nationwide during week 44, 1.4% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI). This percentage is below the national baseline of 2.1%. (ILI is defined as 
fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.) 
 
Additional data are available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by 
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, 2015-2016 and Selected Previous Seasons 
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.5% to 3.1% during 
week 44. All 10 regions reported a proportion of outpatient visits for ILI below their region-specific 
baseline levels.   
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Region 6 - AR, LA, NM, OK, TX
0
2
4
6
8
10
12
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
Week
%
 o
f V
is
its
 fo
r I
LI
  
Region 3 - DE, DC, MD, PA, VA, WV
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Region 4 - AL, FL, GA, KY, MS, NC, SC, TN
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Region 5 - IL, IN, MI, MN, OH, WI
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Region 7 - IA, KS, MO, NE
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Region 8 - CO, MT, ND, SD, UT, WY
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Region 9 - AZ, CA, HI, NV
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Region 10 - AK, ID, OR, WA
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Region 2 - NJ, NY, PR, USVI
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ILINet State Activity Indicator Map: Data collected in ILINet are used to produce a measure of ILI 
activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI 
and are compared to the average percent of ILI visits that occur during weeks with little or no 
influenza virus circulation. Activity levels range from minimal, which would correspond to ILI activity 
from outpatient clinics being below, or only slightly above, the average, to high, which would 
correspond to ILI activity from outpatient clinics being much higher than average. 
 
During week 44, the following ILI activity levels were experienced: 
 Puerto Rico experienced moderate ILI activity. 
 New York City and all 50 states experienced minimal ILI activity. 
 Data were insufficient to calculate an ILI activity level from the District of Columbia. 
 
 
 
*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a 
state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city 
could cause the state to display high activity levels. 
Data collected in ILINet may disproportionally represent certain populations within a state, and therefore, may not accurately depict the 
full picture of influenza activity for the whole state. 
Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map is based on reports 
from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received. 
Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of 
data completeness with data presented by the state likely being the more complete. 
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
influenza viruses, but does not measure the severity of influenza activity. 
  
During week 44, the following influenza activity was reported: 
 Widespread influenza activity was reported by Guam. 
 Regional influenza activity was reported by Puerto Rico. 
 Local influenza activity was reported by four states (Hawaii, Iowa, Massachusetts, and 
Oregon). 
 Sporadic influenza activity was reported by the District of Columbia and 39 states (Alabama, 
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, 
Illinois, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Missouri, Montana, 
Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, 
North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Texas, Utah, 
Vermont, Washington, West Virginia, Wisconsin, and Wyoming). 
 No influenza activity was reported by the U.S. Virgin Islands and seven states (Idaho, 
Indiana, Kansas, Mississippi, Rhode Island, Tennessee, and Virginia). 
 
 
 
2015-16 Influenza Season – Week 44, ending November 7, 2015           
 
 
 
 
15
 
Additional National and International Influenza Surveillance Information 
 
FluView Interactive: FluView includes enhanced web-based interactive applications that can provide 
dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications 
allow people to create customized, visual interpretations of influenza data, as well as make comparisons 
across flu seasons, regions, age groups and a variety of other demographics. To access these tools, visit 
http://www.cdc.gov/flu/weekly/fluviewinteractive.htm. 
 
U.S. State, territorial, and local influenza surveillance: Click on a jurisdiction below to access the latest 
local influenza information. 
Alabama Alaska Arizona Arkansas California 
Colorado Connecticut Delaware District of Columbia Florida 
Georgia Hawaii Idaho Illinois Indiana 
Iowa Kansas Kentucky Louisiana Maine 
Maryland Massachusetts Michigan Minnesota Mississippi 
Missouri Montana Nebraska Nevada New Hampshire 
New Jersey New Mexico New York North Carolina North Dakota 
Ohio Oklahoma Oregon Pennsylvania Rhode Island 
South Carolina South Dakota Tennessee Texas Utah 
Vermont Virginia Washington West Virginia Wisconsin 
Wyoming New York City Puerto Rico U.S. Virgin Islands 
 
 
World Health Organization: Additional influenza surveillance information from participating WHO member 
nations is available through FluNet and the Global Epidemiology Reports. 
 
WHO Collaborating Centers for Influenza located in Australia, China, Japan, the United Kingdom, and the 
United States (CDC in Atlanta, Georgia). 
 
Europe: WHO/Europe at http://www.flunewseurope.org/ and the European Centre for Disease Prevention 
and Control at 
http://ecdc.europa.eu/en/publications/surveillance_reports/influenza/Pages/weekly_influenza_surveillance_ov
erview.aspx 
 
Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at 
http://www.phac-aspc.gc.ca/fluwatch/. 
 
Public Health England: The most up-to-date influenza information from the United Kingdom is available at 
https://www.gov.uk/government/statistics/weekly-national-flu-reports.  
 
Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not 
constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and 
none should be inferred. CDC is not responsible for the content of the individual organization web pages found 
at these links. 
 
An overview of the CDC influenza surveillance system, including methodology and detailed 
descriptions of each data component, is available at: http://www.cdc.gov/flu/weekly/overview.htm.  
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